Fuat Bicer, Assistant Professor at the Ohio State University Wexner Medical Center, shared a series of posts on X, highlighting GU Oncology abstracts at ASCO26:
1. American Society of Clinical Oncology (ASCO) oncologists driving the field forward.
- ctDNA‑guided care
- Peri‑op IO intensification
- Biomarker‑driven precision
- Smarter. Earlier. More precise
2. Cadonilimab + axitinib in nccRCC:
- ORR ~51%
- G3+ AEs ~60%, worse then Ipi/Nivo
- Promising—but small single race, non-randomized
- Not practice-changing
3. KEYNOTE-564 ctDNA (Abstract 4502)
ctDNA+ to worse DFS
- Low sensitivity (~5–8%)
- High specificity (~98–99%)
- Pembro benefit regardless of ctDNA?
- More ctDNA clearance with pembro
- 64-plex > 16-plex detection
Takeaway:
- Prognostic – good
- Clinical utility – not good
4․ Abstract 4513 (AMBASSADOR HRQOL)
Adjuvant pembro in high-risk MIBC:
- No significant HRQOL decline vs observation
- No clinically meaningful differences across domains
- DFS benefit maintained
5. rBCG + chemo-IO in MIBC:
pCR 65% (!)
- Strong response signal
- Single-arm data
- Signal or real step forward?
6. Promising ADC + IO signal
in perioperative MIBC – but still early and unproven without randomized data, again need more diverse patient population.
7. A4504
Durvalumab + CRT in MIBC:
- 1-yr DFS 79%
- PFS 83%
- OS 96% Feasible with manageable safety
Signal for IO + radiation synergy
8. LBA4511
- Durva HR 0.74
- Durva+trem HR 0.65
Not practice-changing – tox concerns remain
I am not convinced yet giving concern for Pembro even
9. Abstract 4506 EV + PD-L1 in periop MIBC
Shows strong early activity (ORR ~71%, pCR ~48%) Important contribution by Dr. Tom Powles.
Advancing the field continues.
10. Abstract 5002
Spatial transcriptomics model (ST-DoxPCa) refines DOC benefit in mHSPC.
- Benefit only in biomarker-high (HR 0.53)
- No benefit in low AI-driven precision chemo selection
AI-driven precision chemo selection.
11. LBA5003 (Nappi et al.)
miR-371a-3p in early testicular CA (SWOG S1823):
- High specificity and NPV
- Moderate PPV
Strong rule-out biomarker during AS.
12. Abstract 5001
DGC >0.85 identifies benefit from DOC + ADT/ENZ
- Predictive, not just prognostic
- No DOC benefit if GC ≤0.85
Precision intensification in mHSPC.
13. Abstract 5000
Clinico-transcriptomic risk guides AAP in high-risk PCa
- Better patient selection (+~20%)
- Avoid overtreatment (~25% VHR)
Precision > blanket intensification.
Other articles about GU Oncology and Fuat Bicer on OncoDaily.